Assembly Biosciences, Inc.
Every calculator, already run for ASMB
Open the full toolkit →You have the numbers on ASMB. Get the argument.
A written report on which of these readings actually decide the outcome for Assembly Biosciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering ASMBAnalyst Price Target Disagreement for Assembly Biosciences, Inc.
Wall Street's bull case implies +162% from the current price; the bear case implies +82%. A 80% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ASMB
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7…
ASMB — frequently asked
Is ASMB a buy right now?
Wall Street's consensus rating on Assembly Biosciences, Inc. is none across 5 analysts, with a mean price target of $52.00 (+120% vs. the current $23.67). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ASMB overvalued?
ASMB trades at 19.1x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Assembly Biosciences, Inc.?
Analysts covering Assembly Biosciences, Inc. (ASMB) range from a bear-case target of $43.00 to a bull-case high of $62.00, with a mean consensus target of $52.00 across 5 analysts. The spread of $19.00 (80% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Assembly Biosciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Assembly Biosciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ASMB research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Assembly Biosciences, Inc., in minutes. 3 free reports included with every account — no credit card required.